FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback